# Image Eval Diagnostics: iter1_prompt_conditions_sonnet46

## Bucket Counts

- missed node: 9
- extra hallucinated node: 9
- wrong branch direction/label: 9
- variable extraction miss: 9
- ambiguity unresolved: 9

## Per-Case Bucket Distribution

### diabetes_treatment
- missed node: 3
- extra hallucinated node: 3
- wrong branch direction/label: 3
- variable extraction miss: 3
- ambiguity unresolved: 3

### liver_pathology
- missed node: 3
- extra hallucinated node: 3
- wrong branch direction/label: 3
- variable extraction miss: 3
- ambiguity unresolved: 3

### workflow_test
- missed node: 3
- extra hallucinated node: 3
- wrong branch direction/label: 3
- variable extraction miss: 3
- ambiguity unresolved: 3

## Trial Notes

### workflow_test trial 1 - composite 23.83
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram has two separate 'Are They Optimised on treatment?' nodes (one for specialist clinic path, one for lipid lowering therapy path) - mapping is assumed but the upper path (specialist) leads to Consider Lipid Clinic Referral / Refer to specialist while the lower leads to Mark as No Further Action / Send AccuRx.; The 'not coded, assume no' yellow sticky note modifies the 'Under Specialist Clinic?' decision - it is unclear if this is a system default or a user instruction; modelled as a branching action node.; The LDL 2-2.5 branch in the secondary prevention path leads to a 'Hasn't had 6 months of Inclisiran' -> Repeat Lipids -> LDL >2.0 -> Add Ezetimibe path, but the diagram also shows a direct 'Send Lipid Lowering Therapy AccuRx' from the repeat lipids if LDL is not >2; this interpretation may be incorrect.; The 'Consultation' label near the 'Send Lipid Lowering Therapy AccuRx with self booking link' (upper not-optimised path) is ambiguous - it may indicate a consultation step before or after sending the message.; The 'Primary/Secondary Treatment' labels appearing on the left side of the diagram are legend annotations and not flow nodes; they have been omitted from the tree.

### workflow_test trial 2 - composite 27.01
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram shows two separate 'Are They Optimised on treatment?' decision nodes - one for patients under specialist clinic (top path, connecting to Consider Lipid Clinic Referral / Refer to specialist) and one for patients taking lipid lowering therapy. It is ambiguous how the specialist clinic 'optimised' node connects exactly to the upper-right outputs.; The 'not coded, assume no' annotation near 'Under Specialist Clinic?' is ambiguous - it suggests a default value of No but it is unclear if this is a system default or a user instruction.; The flow from 'Under Specialist Clinic? > false' branches to both 'Normal or Raised?' and 'Are They Optimised on treatment?' (upper) simultaneously, which is unusual for a tree - it may represent a different entry point or parallel path.; The 'Primary/Secondary Treatment' label appears twice as a yellow annotation box pointing to different branches; its exact role in the logic is unclear.; The 'LDL 2-2.5' branch and 'LDL ≤ 2' branch from Assess LDL - it is unclear whether LDL 2-2.5 means 2.0 to 2.5 inclusive and how it relates to the LDL ≥ 2.6 branch (these should be exhaustive but the diagram labels are ambiguous).

### workflow_test trial 3 - composite 22.59
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The upper 'Are They Optimised on treatment?' branch (under specialist clinic) has two sub-paths leading to 'Consider Lipid Clinic Referral' and 'Refer to specialist' - the exact conditions distinguishing these two outputs are not clearly labeled in the diagram.; The 'not coded, assume no' label near the 'Under Specialist Clinic?' decision is ambiguous - it is unclear if this is a default assumption or a separate branch condition.; The 'Primary/Secondary Treatment' label appears twice in the diagram (bottom-left corner) as a loopback reference - it is unclear which exact node this loops back to.; The 'No' branch from 'Are They Optimised on treatment?' (upper/specialist branch) leads to a 'Send Lipid Lowering Therapy AccuRx' followed by 'Consultation' - but the flow continues in an unclear way after consultation.; The boundary between LDL 2-2.5 and LDL ≥2.6 paths from 'Assess LDL' could be more precisely defined (inclusive/exclusive boundaries).

### diabetes_treatment trial 1 - composite 19.95
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram shows the 'Not tolerated** switch to' branch leading to the Ozempic/GLP initiation path, but it is unclear whether this path bypasses dual/triple therapy steps or goes directly to Ozempic titration. The modelling here routes to a BMI check for GLP initiation.; The 'Despite Optimisation and maximally tolerated dose A1C >58' node appears on the right side of the diagram and may apply to both the BMI<23 (no GLP) branch and after Ozempic in the non-CVD pathway. The exact branching logic is ambiguous.; It is unclear whether 'Add GLP' feeds into a separate prognostic value decision or whether Ozempic/Mounjaro are alternatives at the same level. The diagram shows both 'High prognostic value -> Ozempic' and 'Low prognostic Value -> Mounjaro' side by side.; The 'Minimum BMI for GLP Initiation is 23' box appears both in the CVD/Risk not-tolerated branch and in the main no-CVD triple therapy branch; it may be a shared reference annotation rather than a decision node.; The flow for 'Symptoms & New A1c >58' with 'Admission required?' is shown to the left, and whether it applies before or after the CVD risk check is slightly ambiguous in the diagram layout.

### diabetes_treatment trial 2 - composite 17.26
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram shows 'Symptoms & New A1c >58' branching off from 'Treatment Algorithm' to 'Admission required?' - it is unclear if this branch is only for the 'Not at risk of CVD' path or applies universally before the CVD check.; The 'Not tolerated** switch to' path goes to 'Minimum BMI for GLP Initiation is 23' then to 'Ozempic' - it's unclear what happens if BMI < 23 (no branch shown for false).; The 'Despite Optimisation and maximally tolerated dose A1C >58' node applies to the Ozempic high prognostic value branch - it is ambiguous whether this also applies to the Ozempic in the CVD/not-tolerated pathway.; The diagram shows 'Ozempic' and 'Mounjaro' as separate outcomes after 'High prognostic value' / 'Low prognostic Value' but Refer to Insulin Initiator also appears after A1c not controlled on Ozempic in the triple therapy path - these may represent the same node or different instances.; The flow from the CVD pathway's SGLT2i node onwards (A1c not controlled -> Ozempic -> A1c not controlled -> Refer to Insulin Initiator) is partially overlapping with the non-CVD triple therapy path; the exact branching is ambiguous from the image.

### diabetes_treatment trial 3 - composite 19.27
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram shows 'Despite Optimisation and maximally tolerated dose A1C >58' leading to 'Refer to Insulin Initiator' — it is unclear if this is a separate branch or continuation of the Ozempic path in the CVD pathway.; The 'Not tolerated** switch to' arrow in the CVD pathway seems to bypass SGLT2i and go directly toward the Ozempic/BMI check — confirm if this is correct.; The dual therapy node shows 'Gliptin Or Pioglitazone Or Gliclazide' as alternatives (Or), not sequential — modeled as a single action node but the actual choice depends on additional patient criteria not captured here.; The 'Minimum BMI for GLP Initiation is 23' check appears in the CVD pathway but its position relative to SGLT2i intolerance vs. A1c uncontrolled on SGLT2i is ambiguous.; The Symptoms & New A1c >58 branch appears to feed into the Admission required? decision which then loops back — the exact routing for 'No admission required' back into the main Metformin path for non-CVD patients is inferred.

### liver_pathology trial 1 - composite 11.4
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram has multiple feedback loops and arrows connecting distant nodes (e.g., Review Result connecting back to Telephone Consultation, Phase 4 Bloods referenced multiple times), which cannot be fully represented as a pure tree without duplication of nodes.; The 'Request Liver USS' node appears before Phase 4 Bloods as a separate branch from FIB4/NAFLD scoring but the exact branching logic in the diagram is ambiguous.; The FIB-4 Categories and NAFLD Fibrosis Score Categories appear as parallel branches from Phase 4 Bloods; the exact relationship and which takes precedence is not fully clear.; The 'Fibrous Scan if available' step's relationship to FIB-4 Categories vs NAFLD is ambiguous — it appears to bridge both tracks.; The exact thresholds for FIB-4 age-adjusted cutoffs (1.3, 2.0 for age 65+, 2.67) and NAFLD score ranges (-1.455, 0.675) are represented as enum categories in inputs due to tree structure limitations.

### liver_pathology trial 2 - composite 9.3
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The workflow contains cycles (e.g., Phase 4 Bloods feeds back into Telephone Consultation, and the NAFLD/FIB-4 branches also loop back). A strict tree representation cannot capture these loops without duplicating nodes; duplicate leaf stubs have been added where cycles occur.; The 'Mandatory Testing' and 'Conditional Testing' branches run in parallel in the diagram, but a tree can only represent sequential/branching paths. The mandatory testing (Wilsons/A1AT) and conditional testing branches have been serialized here.; The FIB-4 age-specific thresholds (e.g., <1.3 or <2.0 if age >65; >2.67 at any age; >1.3 or >2.0 if age >65 = Intermediate/High Risk) are collapsed into simple FIB-4 score comparisons without the age interaction in the condition object.; The 'High Risk' FIB-4 category (>2.67) and its path to Phase 4 Bloods and secondary care referral is referenced but not fully distinct from the Intermediate risk path in the diagram; both appear to lead to Fibrous Scan or Phase 4 Bloods.; The 'Review Result' node appears to be a merge/join point receiving results from multiple test branches (Wilsons, Haemochromatosis, PBC, Autoimmune), which cannot be modeled as a tree without duplication.

### liver_pathology trial 3 - composite 11.21
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram has many interconnected paths and feedback loops (e.g., Review Result feeding back to Telephone Consultation, Phase 4 Bloods appearing multiple times). A strict tree structure cannot fully represent these cycles without duplicating nodes.; The 'Need to rationalise which Additional tests should be done for rare conditions' box and its connection to Phase 4 Bloods is ambiguous in terms of exact branching logic.; The FIB-4 and NAFLD score thresholds for age >=65 adjustments are partially visible; exact cutoffs for all branches may not be fully captured.; The 'Raised IgG >0.675' path leading to Autoimmune Hepatitis screens and its downstream connection back to Review Result is ambiguous.; The Fibrous Scan branch and High Risk (>2.67 at any age) path both seem to lead to Phase 4 Bloods and then Refer to Secondary Care, but the exact branching from FIB-4 categories is hard to trace precisely.
